These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. From the challenge to the reassessment of the Women's Health Initiative: a personal initiative for women's health. Gambacciani M; Genazzani AR Gynecol Endocrinol; 2006 Mar; 22(3):115-6. PubMed ID: 16835071 [No Abstract] [Full Text] [Related]
3. Lessons learned from the WHI: HRT requires a cautious and individualized approach. Aubuchon M; Santoro N Geriatrics; 2004 Nov; 59(11):22-6. PubMed ID: 15615157 [TBL] [Abstract][Full Text] [Related]
4. A clinician's review of the WHI-related literature. Speroff L Int J Fertil Womens Med; 2004; 49(6):252-67. PubMed ID: 15751264 [TBL] [Abstract][Full Text] [Related]
5. NIH and WHI: time for a mea culpa and steps beyond. Utian WH Menopause; 2007; 14(6):1056-9. PubMed ID: 17975521 [TBL] [Abstract][Full Text] [Related]
6. Clinical appraisal of the Women's Health Initiative. Speroff L J Obstet Gynaecol Res; 2005 Apr; 31(2):80-93. PubMed ID: 15771632 [No Abstract] [Full Text] [Related]
7. Consequenses for HRT following the HERS II and WHI reports: the primum non nocere is important, but translation into quo vadis is even more essential. Skouby S Acta Obstet Gynecol Scand; 2002 Sep; 81(9):793-8. PubMed ID: 12225293 [TBL] [Abstract][Full Text] [Related]
8. Be careful of what you wish for: putting the WHI Estrogen/Progestin and HERS II Trials in perspective. Randolph JF; Medscape Womens Health; 2002; 7(4):7. PubMed ID: 12466739 [No Abstract] [Full Text] [Related]
9. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy? Shulman LP J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108 [No Abstract] [Full Text] [Related]
10. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI. Clanget C; Hinke V; Lange S; Fricke R; Botko R; Pfeilschifter J Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):529-33. PubMed ID: 16235155 [TBL] [Abstract][Full Text] [Related]
11. Timing of hormone therapy influences breast cancer risk. Harv Womens Health Watch; 2011 Apr; 18(8):7. PubMed ID: 21544975 [No Abstract] [Full Text] [Related]
12. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response. Hartsfield CL; Connelly MT; Newton KM; Andrade SE; Wei F; Buist DS J Natl Cancer Inst Monogr; 2005; (35):113-5. PubMed ID: 16287896 [TBL] [Abstract][Full Text] [Related]
13. Postmenopausal hormone therapy and breast cancer. Prescrire Int; 2009 Apr; 18(100):66-7. PubMed ID: 19585723 [TBL] [Abstract][Full Text] [Related]
14. A personal initiative for women's health: to challenge the Women's Health Initiative. Genazzani AR; Gambacciani M Gynecol Endocrinol; 2002 Aug; 16(4):255-7. PubMed ID: 12396552 [No Abstract] [Full Text] [Related]
16. NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk and lack of overall benefit. South Med J; 2002 Aug; 95(8):795-7. PubMed ID: 12190211 [No Abstract] [Full Text] [Related]
17. Re-think HRT: behind the scene of perceptions. Pines A Climacteric; 2008; 11(6):443-6. PubMed ID: 18991073 [No Abstract] [Full Text] [Related]
18. Breast cancer: the role of hormone therapy. Creasman WT Semin Reprod Med; 2005 May; 23(2):167-71. PubMed ID: 15852202 [TBL] [Abstract][Full Text] [Related]
19. Postmenopausal hormone therapy and cardiovascular disease in women. Stefanick ML Nutr Metab Cardiovasc Dis; 2010 Jul; 20(6):451-8. PubMed ID: 20554177 [TBL] [Abstract][Full Text] [Related]
20. The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program. Hillman JJ; Zuckerman IH; Lee E J Womens Health (Larchmt); 2004 Nov; 13(9):986-92. PubMed ID: 15665655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]